Debiopharm Group Leads Round for Spinomix
Debiopharm Group led a $3 million Series A investment for Spinomix SA, a Swiss company focused on molecular diagnostic technologies. Debiopharm Group is a Swiss-based global biopharmaceutical group of companies.
9 January 2013•3 mins read
